SummaryShort summary of a recent publication, written by scientific experts.
Published: 26 Dec 2018
Five biomarkers improve risk assessment for adverse outcomes in ischemic stroke patients
Considering levels of high-sensitivity C-reactive protein (hsCRP), complement C3, matrix metalloproteinase-9 (MMP-9), hepatocyte growth factor (HGF), and antiphosphatidylserine antibodies (aPS) in addition to established stroke risk factors could significantly improve risk assessment for adverse outcomes in ischemic stroke patients.
Why this matters
Established stroke risk factors do not fully reflect pathophysiologic pathways and outcomes.